Shanghai, Gembloux, Belgium, and Heidelberg, Germany - Jan. 4, 2024 - Full-Life Technologies ("Full-Life"), a fully integrated global radiotherapeutics company, today announced the completion of $63.3 million financing, comprised of $47.3 million in Series B equity financing and $16 million in loan facilities.

Gembloux, Belgium - Dec. 08, 2023 - Full-Life Technologies (Full-Life), a fully integrated global radiotherapeutics company, today announced the construction of its new Good Manufacturing Practices (GMP) compliant manufacturing facility in Gembloux, Belgium, for radiopharmaceuticals.

Full-Life Technologies announce that it has closed on an important land purchase in Wallonia, Belgium, and signed a purchase agreement to build a state-of-the-art, manufacturing facility to produce radiopharmaceuticals to Good Manufacturing Practice (GMP).

Full-Life Technologies today announced the appointments of Steffen Heeger, MD, PhD, as Chief Medical Officer (CMO) and Fa Liu, PhD as Chief Scientific Officer (CSO).

Acquisition accelerates Full-Life's transformation into clinical stage radiopharmaceutical company, leveraging its European-focused Radiotechnology and Development Platform.